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Grape Seed Polyphenol Extract and Cognitive Function in Healthy 
Young Adults: a randomised, placebo-controlled, parallel-groups 
acute-on-chronic trial 
Grapes are polyphenol-rich, and grape juice intake has shown cognitive benefits in 
middle-aged females and older adults with mild cognitive impairment. Extracts obtained 
from grape seeds have similarly been associated with cognitive benefits in older adults. 
The aim of this research was to investigate whether a highly purified grape seed-derived 
polyphenol extract was associated with cognitive benefits in healthy young adults 
following a single acute dose, and chronically following repeated daily dosage over 12 
weeks. Following an acute-on-chronic, parallel groups, randomised, double-blind, 
placebo-controlled design, sixty adults aged 18–30 consumed either a 400 mg grape 
seed polyphenol extract (GSPE, n = 30) or a placebo (n = 30). Cognitive function was 
assessed acutely at baseline and 2, 4 and 6 h post consumption, and chronically at 6 and 
12 twelve weeks with a computerised battery of multiple cognitive tests. Mood was 
assessed with the Positive and Negative Affect Schedule. Linear marginal model 
analysis with baseline included as a covariate did not reveal a consistent pattern of 
cognitive benefits following the GSPE relative to the placebo either acutely or 
chronically when considering all outcome measures. GSPE was associated with some 
improvements in reaction time (acutely) and psychomotor skill (chronically), however 
the placebo was also associated with some benefits to reaction time and memory. 
Therefore, a 400 mg GSPE did not consistently improve cognitive function in healthy 
young adults. These findings suggest that younger, healthy populations are perhaps less 
sensitive to polyphenol extract doses <400mg relative to older, or cognitively 
compromised populations. 




Epidemiological studies suggest a positive association between intake of polyphenol-
rich fruits, such as grapes, and benefits to cognitive function (1). This is supported by 
systematic reviews of polyphenol human intervention studies which indicate that single 
acute doses (2) and chronic daily consumption over several weeks (3) of polyphenol 
rich-foods has neuropsychological benefits. Grapes (Vitis Vinifera) contain a range of 
polyphenols (4) which can be categorised into flavonoids (flavan-3-ols, flavonols, 
anthocyanins and flavones), and non-flavonoids (phenolic acids and stilbenes). 
Numerous health benefits have been associated with grape polyphenols relating to anti-
inflammatory properties, cardiovascular outcomes, improved insulin sensitivity, 
reduced risk of type 2 diabetes, and neuroprotective mechanisms (5). For example, in 
rodent models supplementation with an extract containing grape and blueberry was 
associated with increased brain derived neurotrophic factor (BDNF; a protein which 
contributes to neuroplasticity; (6)), and increased motor and memory functions have 
been observed in healthy aged rats following intake of grape-derived products (7, 8). 
Further support for a neuroprotective mechanism of action (see (9) for review) comes 
from positive correlations between increased hippocampal neurogenesis in rodents and 
presence of grape-derived polyphenols and their metabolites in the bloodstream (6). In 
humans, BDNF concentrations have been shown to increase following one month of 
daily grape juice consumption (10) and cognitive benefits have been shown in a number 
of randomised controlled trials. For example, regular daily grape juice over three 
months was shown to improve performance on both a neuropsychological test battery 
and measures of driving performance in stressed middle-aged working mothers (11), 
and improved memory function in older adults with mild cognitive impairment (12, 13). 
A single acute dose of grape juice has also been associated with improved attention in 
 
 
healthy young adults (14). Despite the apparent cognitive benefits for grape juice, there 
are limited studies using grape seed extracts; the seeds can contain up to 70% of the 
extractable polyphenols found in whole grapes (15), thus it can be hypothesised that 
these extracts contain sufficient polyphenols to induce effects seen with the whole juice. 
A grape-seed extract (from Vitis Vinifera) has been shown to improve some aspects of 
cognitive function in older adults aged 55-75 years. This included subtle improvements 
(relative to baseline) in an assessment designed to detect mild cognitive impairment and 
dementia (the Mini Mental State Examination) and aspects of language, attention and 
delayed memory on a test battery following daily intake of the 250mg extract over 
twelve weeks. Aspects of mood were also found to improve, including reduced 
depression and anxiety scores. Whilst there is, therefore, tentative evidence that grape 
seed extracts may benefit the brain in older adults, further investigation is required to 
explore whether these benefits extend to younger populations, and also build on 
evidence from grape juice, and other aforementioned polyphenol studies, to explore 
whether acute as well as chronic effects exist. Therefore, the aim of the present study 
was to investigate whether a highly purified grape seed-derived polyphenolic extract 
from Vitis Vinifera was associated with cognitive benefits following a single acute 
dose, and chronically following repeated daily dosage over 12 weeks (with mid-point 
testing at 6 weeks) in healthy young adults. 
Method 
Design 
The study was registered on ClinicalTrials.Gov (Identifier NCT03526406). An acute-
on-chronic, parallel groups, randomised, double-blind, placebo-controlled design was 
implemented. Participants were randomly allocated to the grape seed polyphenol extract 
 
 
(GSPE) or placebo condition using an established randomisation procedure. To 
maintain double-blinding the extracts were labelled with codes by the manufacturer, 
which was revealed to the research team following completion of the analysis.  For the 
acute design, participants were tested at baseline (prior to treatment), and at two, four 
and six hours post treatment consumption. For the chronic design participants were 
tested at baseline (Visit 1; prior to treatment), six weeks (Visit 2) and twelve weeks 
(Visit 3) following daily treatment. Intervention compliance was monitored through the 
use of a self-report form where participants recorded days when they had forgotten to 
take their allotted intervention capsule. Remaining capsules were counted when 
participants returned for testing at Visit 2 and Visit 3, and numbers were cross-checked 
with the self-report form. For both the acute and chronic design, outcome measures 
were cognitive function and mood. A favourable opinion for conduct was attained from 
the University of Reading School of Psychology and Clinical Language Sciences 
Research Ethics Committee and this study follows the principles of the Declaration of 
Helsinki. 
Intervention 
The GSPE and the placebo were identical in appearance and delivered in capsule form 
(made of bovine gelatine), each matched for weight and containing 400 mg powder. The 
exact calorie conternt of each was unknown. The GSPE was a 400 mg mix of purified 
grape seed-derived polyphenolic extracts from Vitis Vinifera (MegaNatural AZ; 
Polyphenolics Inc., Madera, CA, USA) containing catechin, epicatechin, 
proanthocyanidins, and derivatives of catechin and epicatechin (epicatechin gallate) 
based on in-house analysis by Polyphenolics Inc. The placebo contained 400 mg 
maltodextrin. Both the GSPE and placebo powders contained trace amounts of modified 




Sixty healthy participants (GSPE n=30 and placebo n=30) aged 18-30 were recruited 
via opportunistic sampling. Sample size was determined by power analysis using 
GPower 3.1., assuming a medium effect size (2), 30 participants per intervention group 
were needed to detect a significant difference between groups with an alpha of 0.05 and 
80% statistical power. Exclusion criteria were any diagnosed disease or illness, 
including psychiatric or neurological conditions, consumption of any medication or 
nutritional supplements, participation in any clinical trial within previous 6 months, 
alcohol consumption >14 units/week, smoking, vegetarian or vegan, pregnancy, >4 
hours/week vigorous exercise. All participants were required to give informed consent 
before taking part. 
Outcome measures 
Cognitive function was assessed with a computerised battery of tests administered in a 
fixed order lasting approximately 45 minutes including the Auditory Verbal Learning 
Test (AVLT), Serial Subtraction 3s and 7s, the Modified Attention Network Test 
(ANT), Simple and Complex Finger Tapping and the Switching Task.  
The AVLT required participants to listen to a recording of 15 words (list A) following 
which there was a 2 minutes period to orally recall as many words as possible. This was 
repeated a further 4 times, followed by presentation and recall of a new ‘interference’ 
list (List B), immediately followed by a final recall of List A. Following a 25 minute 
period during which the remaining cognitive tests were presented, delayed recall of List 
A took place, followed by a recognition task whereby participants distinguished List A 
words from List B words and an additional 20 previously unseen foils. Different word 
lists, matched for concreteness and familiarity, were administered in a counterbalanced 
 
 
order at each test session. Dependent variables were the total recall at each repetition, 
delayed recall, learning (List A recall 5 – List A recall 1) proactive interference (List A 
recall 1 – List B recall 1), retroactive interference (List A recall 5 – List A recall 6), and 
number of words correctly recognised.   
Serial Subtraction 3s and 7s provided a measure of working memory, whereby a 
random number between 800 and 999 was presented on screen and participants 
subtracted backwards (in 3s or 7s), answering using a number pad as quickly as possible 
over 2 minutes. Dependent variables were number of correct responses and errors.  
The ANT is an executive function task whereby participants viewed blocks of arrows 
presented on screen in rapid succession and indicated with a key press (left or right 
arrow) the direction of the arrow closest to a central fixation point. The target arrow was 
either flanked by arrows pointing in the same (congruent) or opposite (incongruent) 
direction, or was not flanked at all. On selected trials, spatial cues were introduced 
immediately prior to the appearance of the arrows. Task load was further manipulated 
by increasing or decreasing the number of flanking arrows across multiple trials. 
Participants completed 36 practice trials, followed by 160 trials in the main task. 
Dependent variables were reaction time and accuracy.  
Simple Finger Tapping involved pressing the “c” key as many times as possible with 
the index finger of the dominant hand for a duration of 30 s. Complex Finger Tapping 
followed the same procedure except the required response was “c”,”b”, “v”, “n” using 
the first, third, second and fourth fingers, respectively (or the reverse for left handed 
participants). The dependent variables for this psychomotor function task were the total 
number of correct responses for simple tapping, and the total number of correct 
sequences for complex finger tapping.  
 
 
The Switching Task assessed executive function. Participants viewed eight equally 
spaced radii of a circle displayed in such a way that there were four equally spaced 
segments above and below a bold line. A stimulus digit selected from between 1 – 9 
(excluding 5) appeared in each segment in turn in a clockwise direction. Each digit was 
displayed for a duration of 3000 ms, or until the participant responded. Inter-stimulus 
interval was 500 ms. Dependent on whether the stimulus was in the segments above or 
below the bold line, participants performed different tasks. If the number was above the 
bold line, participants discerned whether the stimulus was odd or even by pressing the 
relevant response key, whereas if the number was below the bold line, participants 
discerned whether the number was higher or lower than 5, again by pressing the 
relevant key. The task switched every 4 trials.  For the first 8 rotations of the task, 
participants received feedback on all errors or failures to respond within 3 seconds. This 
data was excluded from the final analysis. Participants then completed 48 rotations of 
the task (containing 96 switch trials and 588 non-switch trials) during which no 
feedback was provided. Dependent variables were accuracy and reaction time. 
Subjective mood was assessed with the PANAS-Now questionnaire, whereby 
participants rated 20 mood adjectives on a scale of 1-5, giving two dependent variables 
Positive and Negative Affect. Mental fatigue was also assessed with a nine point Likert 
scale. These subjective mood variables were recorded at the beginning and end of the 
test battery. A change score was calculated by subtracting the end ratings from those 
recorded at the beginning. Average daily fruit and vegetable consumption was assessed 
using data from the EPIC-Norfolk Food Frequency Questionnaire.  BMI (kg/m2) was 





Participants attended the University of Reading School of Psychology for four separate 
visits; Practice Visit, Visit 1 (week 0), Visit 2 (week 6) and Visit 3 (week 12). For 48 
hours prior to each test visit, participants followed a low polyphenol diet requiring 
restriction of foods including fruits, vegetables, juices, chocolate, tea & coffee 
(caffeinated beverages were only restricted for 24 hours). Compliance was recorded 
with a food diary. Participants were also required to be fasted for 12 hours. Upon arrival 
(8am-9am) participants consumed a low polyphenol breakfast of two croissants, 
consumed within 15 minutes. At the Practice Visit a practice version of the cognitive 
battery (data not recorded) and mood measures were completed. Participants completed 
the EPIC-Norfolk FFQ to record their habitual diet, and height and weight measures 
were taken.  At Visit 1, 2 and 3 the mood measures and cognitive battery were 
administered immediately after breakfast. At Visit 1, the first treatment was consumed 
following completion of the baseline cognitive battery (at Visits 2 and 3 participants 
consumed their treatment immediately after completion of the mood/cognitive 
measures). At Visit 1 only, a standardised lunch (cheese sandwich and crisps) was 
provided at the end of the 2h cognitive battery, and two further mood/cognitive 
assessments were administered 4 and 6 hours post treatment consumption. During all 
breaks participants resumed their normal daily activities but were asked to avoid all 
food and beverages other than water, and to avoid vigorous exercise. After testing was 
completed, participants were provided a supply of capsules, and returned 6 weeks later 
for Visit 2. At the end of Visit 3 the EPIC- Norfolk food frequency questionnaire was 
completed (only taking into account their diet during the 12 week study period) and 




For the chronic analysis, a linear marginal model (LMM) using an unstructured 
covariance matrix to model Visit 2 (week 6) and Visit 3 (week 12) with baseline Visit 1 
(week 0) as a repeated covariate was applied. Visit and Intervention Group were 
included as fixed factors in the model. For analysis of the acute data, an unstructured 
covariance matrix to model two, four and six hours, with baseline as a repeated 
covariate was applied. Time and Intervention Group were included as fixed factors in 
the model. Post hoc pairwise comparisons were used to investigate any significant 
effects of Intervention Group. A Bonferroni correction was applied to all multiple 
comparisons. For all RT data, only correct responses were included. Z score analysis 
was used to identify outliers (z score>3.29 were removed prior analysis; (16). All 
outcome measures met the required assumptions of normality. Raw data from this 
project will be openly available from the University of Reading Research Data Archive 
at http://researchdata.reading.ac.uk/. 
Results 
Sixty participants completed the study. The CONSORT diagram is shown in Figure 1. 
Table 1 outlines sample characteristics, for which there were no significant differences 
between treatment groups. 
[Figure 1 here] 
[Table 1 here] 
Acute analysis 
The majority of outcomes showed no significant effects of treatment (see Table 2). 
There was evidence that GSPE was associated with faster responses for the Switching 
Task across all time points, as indicated by a main effect of treatment 
 
 
(F[1,459]=10.13,p<.01). This was further supported by the significant treatment*time 
interaction (F[2,453]=3.31,p<.05) with pairwise comparisons showing significantly 
faster RT for GSPE relative to placebo at 2hrs and 4hrs (both p<.001). GSPE 
consumption was also associated with benefits for reaction time on the ANT; pairwise 
comparisons showed faster responses at 6hrs relative to 4hrs (p<.001) following a 
treatment*time interaction (F[2,431)=4.45,p<.05). Faster ANT RT was also seen 
between 2hrs and 4hrs following placebo (p<.001), and better performance was 
observed following the placebo relative to the GSPE for AVLT Total Recall 
(F[1,56]=5.56,p<.05), Retroactive Interference (F[1,54]=4.17,p<.05), and Switching 
Task accuracy (F[1,435]=12.19,p<.01] as indicated by main effects of treatment (see 
Table 2). 
[Table 2 here] 
Chronic analysis 
Similarly to the acute analysis, the majority of outcomes showed no significant effects 
of treatment (see Table 3). There was evidence of a GSPE benefit for Simple Finger 
Tapping (treatment*visit interaction F[1,60]=8.36, p<.01) whereby performance 
decreased between weeks 6 and 12 for the placebo (p<.05), with performance 
maintained for GSPE. A treatment*visit interaction was also observed for AVLT Total 
Recall (F[1,53]=6.28,p<.05) with performance better for the placebo group relative to 
the GSPE group at week 6 (p<.05), however, GSPE performance increased between 
week 6 and 12 (p<.05), to a level commensurate with the placebo group. Unexpectedly, 
there was evidence for a slowing in reaction time between weeks 6 and 12 for the GSPE 
on the Switching Task (p<.01) and the ANT (p<.01) as indicated by significant 
treatment*visit interactions (F[1,448)=7.62,p<.01) and (F[1,444]=25.66,p<.001) 
respectively. Table 3 shows that a number of outcomes showed significant main effects 
 
 
of visit. These showed that subjective mood improved between week 6 and 12 as 
indicated by higher ratings of positive affect and lower ratings of fatigue (both p<.05). 
Interestingly, cognitive performance declined on some outcomes between weeks 6 and 
12 as shown by lower accuracy coupled with slower reactions times for the ANT and 
the Switching Task (all, p<.05). 
[Table 3 here] 
Discussion 
In summary, there was limited evidence for cognitive benefits following acute or 
chronic consumption of a 400mg Vitis Vinifera grape seed polyphenol extract in 
healthy adults aged 18-30. Acutely, there were improvements in reaction time 2-4 hours 
post consumption of the extract for two measures of executive function (switching task 
and the ANT), and following chronic dosage of the extract faster finger tapping was 
observed. However, a number of (acute and chronic) positive effects were observed 
following the placebo, and when considering the range of cognitive outcomes assessed 
there were no consistent benefits of the extract. The reaction time and finger tapping 
effects that were associated with the extract can be broadly described as psychomotor 
function. Interestingly, improvements in finger tapping have also been shown in healthy 
young adults following acute flavonoid-rich orange juice intervention, without benefits 
for a number of other cognitive measures (17). Similarly, a grape juice intervention in 
healthy young adults did not show effects on individual cognitive tests, but benefits 
were observed for a composite measure of attention reaction time (14). Psychomotor 
function is a lower order cognitive process which contributes to any cognitive measure 
involving reaction time, and it is plausible that psychomotor function improvements 
will precede benefits on other more complex, higher order cognitive functions, such as 
executive function inhibition tasks (e.g. the ANT and switching task here). In support, a 
 
 
review of acute flavonoid interventions (2) showed that benefits are most consistently 
seen for attention, working memory, and psychomotor processing speed. Here, the 
polyphenol (and flavonoid) dose may have been too small to induce observable benefits 
on the majority of the complex measures of executive function and episodic memory, 
but it may have been sufficient to produce the small, albeit inconsistent effects for 
psychomotor function. However, discussions and interpretations relating to the present 
dose are limited as the exact concentration of polyphenols (or sub-classes) in the grape 
seed extract were not quantified. What is known is that the dose was <400mg given the 
total size of the extract.   
Limited and null cognitive effects of polyphenol interventions in healthy young adults 
have also been reported elsewhere, including resveratrol supplements (18), green tea 
epigallocatechin gallate extracts (19) and a single serving of grape juice (20). Healthy 
young adults, who are at peak cognitive capacity with regards to the lifespan maybe less 
likely to benefit from polyphenol interventions relative to older adults in cognitive 
decline, or children who are experiencing cognitive development. In support, 
polyphenol-rich grape juice has been shown to improve cognitive function in middle-
aged, stressed females (11) and older adults with mild cognitive impairment (12, 13). 
This indicates that grape juice and its constituents (e.g. polyphenols) can benefit the 
brain, particularly in adults with cognitive decline, potentially via neuroprotective 
mechanisms such as improved synaptic plasticity, anti-inflammatory actions, and 
reduced neurodegeneration (9). In support, cerebral physiological benefits have been 
detected following six months grape juice supplementation in healthy older adults; 
cerebral metabolism was seen to decline following the placebo, but these reductions 
were attenuated following the grape juice (21). Furthermore, thirty days grape juice 
supplementation was found to increase levels of BDNF in healthy older adults (10). 
 
 
These mechanistic actions will arguably have lower efficacy in healthy (young) 
populations who do not show increased neuronal oxidative stress or neurodegeneration. 
However, even in older adults, these physiological changes may not always manifest 
observable behavioural changes (10, 21).  
Population differences may, therefore, contribute to inconsistencies between the current 
findings and a twelve week trial of grape seed extract supplementation in older adults 
aged 56-75 years (22), where improvements in general cognitive function were found, 
as assessed with the Mini-Mental State Examination and specific aspects of a 
neuropsychological test battery including attention and memory. However, their non-
parametric analysis model did not consider change from baseline for the extract relative 
to change from baseline for the placebo, and baseline performance for extract and 
placebo were not directly compared. The results therefore warrant further validation. 
This highlights the importance of applying appropriate and rigorous analysis models, 
such as linear mixed and marginal models, which can account for baseline performance 
as a covariate, as applied here. There are numerous recommendations for conducting 
controlled trials of nutritional interventions for health outcomes such as cognitive 
function (e.g. (23)), which should be considered for developing a strong evidence base 
and addressing calls for increasing reproducibility and replication (24).  
A further point of note is that polyphenol supplements may be subject to degradation 
over time. Some of the unexpected findings in the current study could be explained by 
such a degradation of the GSPE capsules. Participants were not given specific storage 
instructions for the capsules, and remaining capsules were not tested for polyphenol 
content at the end of the study. Future work should consider such a measure or include 
the testing of metabolites in plasma or urine throughout the study to continually monitor 
bioactivity.  An additional limitation of the current study is that the young adult 
 
 
population tested was biased towards females. However, analysis of the exclusively 
female sample did not change the reported outcomes. 
Despite the limited evidence here, future research is required to understand the efficacy 
of grape seed polyphenol extracts for cognitive benefits in humans, given that there is 
supportive evidence from rodent studies (e.g. (7, 8)) and human studies with grape juice 
(e.g. (11-14)). Concomitant assessment of behavioural outcomes with consideration of 
the bioavailability of grape polyphenols when consumed as an extract, or indeed as 
whole juice, would advance mechanistic understanding. For example, a review of the 
brain distribution of grape-derived phenolics and metabolites following 
supplementation in rodents indicated that circulation in the blood stream and 
accumulation in brain tissue is low (25). Dose response studies would give an indication 
of the concentrations required to observe behavioural effects, as has been documented 
with peripheral vascular outcomes following flavonoid-rich blueberries (26). The 
important contribution of the gut microbiota for determining individual differences in 
absorption, distribution, metabolism, excretion, bioavailability, and subsequently 
cognitive outcomes has also been highlighted (25). For example, in diabetic rodents, the 
extent of grape polyphenol metabolites found in the plasma and brain tissue following 
supplementation was associated with specific metabolising enzymes in the gut (27). 
There are also likely to be age related differences in the permeability of the blood brain 
barrier (28) and its susceptibility to phenolic metabolites (29), which could contribute to 
the apparently greater cognitive sensitivity of older adults relative to younger adults 
following grape juice and extract supplementation. Future work should examine this, 
and investigate whether the specific phenolics present in grape extract (e.g. flavan-3-ols, 
flavonols, anthocyanins, flavones, phenolic acids, and stilbenes) have different 
contributions. It is also currently unclear how behavioural effects may differ between 
 
 
supplementation from grape juice and grape seed extracts. Currently, this cannot be 
answered as this is one of only two grape seed extract cognitive function studies in 
humans (also (22)), however, it can be hypothesised than any differences will be 
associated with variations in the digestion, metabolism, and subsequent bioavailability 
of whole fruits, juices and extracts. To conclude, this is the first study to specifically 
examine cognitive effects of grape seed extracts in healthy young adults. There were no 
clear, consistent cognitive benefits relative to placebo consumption either acutely over 
six hours or following six and twelve weeks daily consumption.  Further research 
should consider the role of dose, population and individual differences in bioavailability 
of grape seed extract. Given current interest in the facilitation of healthy aging, 
investigation of the optimum doses for the mitigation of cognitive decline in older 
adults appears a priority. 
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Figure 1 CONSORT Diagram  
 
 






Characteristic Mean SD Range Mean SD Range 
p-
value 
Age 21.07 2.41 18-27 20.87 3.03 18-30 0.78 
Gender 3M/27F - - 6M/24F - - - 
BMI (kg/m2) 21.42 3.66 17-32 22.72 3.72 18-37 0.18 
Average Daily Fruit & 
Veg (portions) 




Table 2. Acute data and LMM summary. 
  Placebo 
 
Grape Seed Polyphenol Extract 
      2h 4h 6h 
 
2h 4h 6h 
 
LMM Fixed Effects p-values 
Task Mean SE Mean SE Mean SE 
 





PANAS (out of 50): 
                 
Positive affect 1 22.26 0.77 20.09 0.79 20.09 0.99 
 
22.49 0.79 19.63 0.80 19.66 1.00 
 
<0.001 ns ns 
Positive affect 2 18.35 0.63 17.18 0.72 18.68 0.86 
 
18.62 0.63 16.68 0.72 18.22 0.86 
 
0.004 ns ns 
Positive affect change -4.17 0.70 -3.17 0.81 -1.67 0.94 
 
-4.55 0.71 -3.48 0.83 -1.76 0.96 
 
0.040 ns ns 
Negative affect 1 11.34 0.25 11.03 0.24 11.41 0.23 
 
11.22 0.25 11.36 0.24 11.40 0.24 
 
ns ns ns 
Negative affect 2 12.08 0.38 11.56 0.33 11.68 0.36 
 
11.87 0.38 12.42 0.33 12.94 0.36 
 
ns (0.080) ns 
Negative affect change 0.69 0.34 0.67 0.30 0.35 0.29 
 
0.42 0.34 0.93 0.30 1.15 0.30 
 
ns ns ns 
Mental Fatigue (out of 9): 
                 
Fatigue 1 3.72 0.23 4.22 0.27 4.72 0.32 
 
3.75 0.23 4.28 0.27 5.25 0.32 
 
<0.001 ns ns 
Fatigue 2 5.71 0.26 6.41 0.28 5.97 0.31 
 
5.93 0.26 6.36 0.28 6.79 0.31 
 
0.016 ns ns 
Fatigue change 1.94 0.32 2.14 0.30 1.21 0.27 
 
2.23 0.32 2.13 0.30 1.59 0.27 
 
0.029 ns ns 
Serial 3s & 7s (in 2 minutes): 
                 
Serial 3s score 44.50 1.44 47.34 2.10 48.80 1.91 
 
45.20 1.47 46.76 2.13 46.27 1.95 
 
0.024 ns ns 
Serial 3s errors 2.32 0.33 1.99 0.28 1.52 0.39 
 
1.91 0.33 1.94 0.27 2.61 0.39 
 
ns ns 0.017 
Serial 7s score 21.94 0.89 22.94 1.04 25.04 1.07 
 
23.68 0.91 24.25 1.04 24.49 1.07 
 
0.020 ns ns 
Serial 7s errors 2.62 0.40 2.79 0.35 2.13 0.33 
 
3.05 0.40 3.23 0.35 2.43 0.33 
 
0.017 ns ns 
Finger tapping (in 30 secs): 
                 
Simple 121.94 1.38 122.31 1.44 123.21 1.56 
 
123.55 1.40 121.37 1.47 122.24 1.59 
 
ns ns ns 
Complex 21.09 0.50 21.99 0.60 21.96 0.71 
 
21.24 0.49 21.11 0.59 21.91 0.69 
 
ns ns ns 
AVLT recall (out of 15): 
                 
AVLT Immediate recall 6.21 0.30 6.42 0.30 6.42 0.32 
 
5.77 0.31 6.11 0.31 6.25 0.33 
 
ns ns ns 
AVLT Final recall 13.29 0.27 13.46 0.22 13.25 0.29 
 
13.06 0.28 13.22 0.23 13.30 0.31 
 
ns ns ns 
 
 
  Placebo 
 
Grape Seed Polyphenol Extract 
      2h 4h 6h 
 
2h 4h 6h 
 
LMM Fixed Effects p-values 
Task Mean SE Mean SE Mean SE 
 





AVLT Total recall (out of 75) 54.62 1.17 54.48 1.21 54.17 1.47 
 
50.59 1.21 50.07 1.26 51.74 1.53 
 
ns 0.022 ns 
AVLT Learning 7.02 0.34 6.98 0.35 6.78 0.41 
 
7.31 0.35 6.94 0.36 6.83 0.42 
 
ns ns ns 
AVLT Proactive interference 1.06 0.34 0.58 0.38 0.61 0.39 
 
1.19 0.36 0.97 0.39 1.22 0.41 
 
ns ns ns 
AVLT Retroactive interference 1.32 0.29 1.11 0.29 1.26 0.36 
 
1.80 0.30 2.09 0.30 1.80 0.37 
 
ns 0.046 ns 
AVLT Delayed recall 10.16 0.52 10.33 0.53 9.81 0.60 
 
9.42 0.54 9.31 0.55 9.09 0.63 
 
ns ns ns 
AVLT recognition: 
                 
Yes responses (out of 15) 12.95 0.27 12.45 0.31 12.75 0.34 
 
12.49 0.27 12.16 0.31 12.28 0.35 
 
ns ns ns 
No reponses (out of 35) 33.95 0.23 33.93 0.23 34.30 0.17 
 
34.17 0.24 34.07 0.23 34.27 0.17 
 
ns ns ns 
ANT: 
                 
Accuracy (%) 0.97 <0.01 0.96 <0.01 0.97 <0.01 
 
0.97 <0.01 0.96 <0.01 0.97 <0.01 
 
0.036 ns ns 
Reaction time (ms) 449.82 5.31 437.87 5.30 435.31 5.24 
 
451.17 5.22 448.29 5.22 439.03 5.18 
 
<0.001 ns 0.012 
Switching task: 
                 
Accuracy (%) 0.95 <0.01 0.95 <0.01 0.95 <0.01 
 
0.94 <0.01 0.93 <0.01 0.94 <0.01 
 
0.003 0.001 (0.051) 
Reaction time (ms) 764.79 6.78 760.32 8.42 724.39 7.98   732.25 6.78 721.47 8.42 714.01 7.88   <0.001 0.002 0.037 






Table 3. Chronic data and LMM summary. 
  Placebo 
 
Grape Seed Polyphenol Extract 




LMM Fixed Effects p-values 
Task Mean SE Mean SE 
 
Mean SE Mean SE 
 
Visit Treatment Treatment x Visit 
PANAS (out of 50): 
             Positive affect 1 22.88 0.99 24.68 1.07 
 
23.49 0.99 25.43 1.07 
 
0.016 ns ns 
Positive affect 2 19.64 1.11 21.00 1.09 
 
18.89 1.13 20.18 1.12 
 
(0.074) ns ns 
Positive affect change -2.74 0.88 -3.09 0.89 
 
-4.33 0.88 -4.60 0.89 
 
ns ns ns 
Negative affect 1 12.17 0.51 12.05 0.58 
 
13.09 0.50 12.92 0.57 
 
ns ns ns 
Negative affect 2 12.00 0.54 12.31 0.60 
 
13.59 0.53 14.15 0.59 
 
ns 0.015 ns 
Negative affect change -0.19 0.51 -0.02 0.42 
 
0.49 0.51 1.22 0.42 
 
ns (0.066) ns 
Mental Fatigue (out of 9): 
             Fatigue 1 4.35 0.32 3.39 0.34 
 
4.35 0.32 3.81 0.34 
 
0.023 ns ns 
Fatigue 2 5.77 0.35 5.07 0.34 
 
5.59 0.35 5.43 0.34 
 
(0.084) ns ns 
Fatigue change 1.43 0.31 1.69 0.28 
 
1.24 0.31 1.61 0.28 
 
ns ns ns 
Serial 3s & 7s (in 2 minutes): 
             Serial 3s score 47.94 1.58 49.47 2.08 
 
44.31 1.58 44.79 2.09 
 
ns (0.060) ns 
Serial 3s errors 2.06 0.38 2.66 0.40 
 
2.28 0.38 2.25 0.40 
 
ns ns ns 
Serial 7s score 24.20 1.07 23.29 0.94 
 
24.62 1.07 24.40 0.94 
 
ns ns ns 
Serial 7s errors 2.40 0.46 2.33 0.41 
 
2.71 0.47 2.83 0.41 
 
ns ns ns 
Finger tapping (in 30 secs): 
             Simple 124.36 1.66 121.43 1.73 
 
123.24 1.66 125.71 1.73 
 
ns ns 0.005 
Complex 20.48 0.73 21.14 0.67 
 
20.57 0.72 21.03 0.65 
 
ns ns ns 
AVLT recall (out of 15): 
             AVLT Immediate recall 7.55 0.31 7.41 0.39 
 
6.58 0.32 7.20 0.41 
 
ns ns ns 
AVLT Final recall 13.94 0.22 13.73 0.25 
 
13.56 0.23 13.74 0.26 
 
ns ns ns 
AVLT Total recall (out of 75) 59.00 1.04 57.66 1.22 
 
54.75 1.08 57.43 1.30 
 
ns ns 0.015 
 
 
  Placebo 
 
Grape Seed Polyphenol Extract 




LMM Fixed Effects p-values 
Task Mean SE Mean SE 
 
Mean SE Mean SE 
 
Visit Treatment Treatment x Visit 
AVLT Learning 6.38 0.35 6.31 0.42 
 
6.84 0.37 6.53 0.44 
 
ns ns ns 
AVLT Proactive interference -0.17 0.41 0.04 0.36 
 
0.12 0.42 0.40 0.39 
 
ns ns ns 
AVLT Retroactive interference 0.85 0.25 0.65 0.25 
 
0.99 0.27 1.24 0.26 
 
ns ns ns 
AVLT Delayed recall 12.78 0.36 12.64 0.32 
 
12.01 0.37 12.29 0.34 
 
ns ns ns 
AVLT recognition: 
             Yes responses (out of 15) 13.84 0.25 13.78 0.26 
 
13.41 0.26 13.54 0.26 
 
ns ns ns 
No responses (out of 35) 34.58 0.16 34.41 0.18 
 
34.46 0.16 34.51 0.17 
 
ns ns ns 
ANT: 
             Accuracy (%) 0.98 <0.01 0.97 <0.01 
 
0.98 <0.01 0.97 <0.01 
 
0.039 ns ns 
Reaction time (ms) 443.04 4.35 441.76 4.45 
 
449.25 4.35 457.53 4.45 
 
0.044 (0.072) 0.006 
Switching task: 
             Accuracy (%) 0.96 0.01 0.95 0.01 
 
0.95 0.01 0.94 0.01 
 
<0.001 ns ns 
Reaction time (ms) 746.91 20.26 732.75 20.31   748.73 19.97 792.00 20.08   0.011 ns <0.001 
Reported values are estimated marginal means with baseline as covariate; ns indicates non-significant effect p>0.10, brackets around p-value indicate non-
significant trend (0.05<p<0.10) 
 
 
 
 
